HLS Therapeutics (FRA:74D) Cyclically Adjusted Book per Share: €3.63 (As of Mar. 2026)


FRA:74D HLS Therapeutics Inc FRA:74D
63 GF Score
Price €2.42
GF Value €2.59
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Cyclically Adjusted Book per Share?

HLS Therapeutics FRA:74D -3.97% 63 Cyclically Adjusted Book per Share is €3.63 as of Mar. 2026. GuruFocus rates FRA:74D with a GF Score™ of 63/100 and a GF Value™ of €2.59 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

HLS Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €1.620. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, HLS Therapeutics's average Cyclically Adjusted Book Growth Rate was 1.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 3.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 7.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 13.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of HLS Therapeutics was 22.00% per year. The lowest was -5.30% per year. And the median was 3.50% per year.

As of today (2026-07-04), HLS Therapeutics's current stock price is €2.42. HLS Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €3.63. HLS Therapeutics's Cyclically Adjusted PB Ratio of today is 0.67.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of HLS Therapeutics was 6.48. The lowest was 0.51. And the median was 1.39.


HLS Therapeutics  (FRA:74D) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

HLS Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.42/3.63
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of HLS Therapeutics was 6.48. The lowest was 0.51. And the median was 1.39.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


HLS Therapeutics Cyclically Adjusted Book per Share Related Terms


HLS Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for HLS Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics Cyclically Adjusted Book per Share Chart

HLS Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.26 3.70 3.77 3.97 3.54

HLS Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.72 3.61 3.53 3.54 3.63

FRA:74D vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:74D
63GF Score
HLS Therapeutics Inc FRA:74D
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HLS Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, HLS Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.62/132.2600*132.2600
=1.620

Current CPI (Mar. 2026) = 132.2600.

HLS Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 1.806 102.002 2.342
201609 1.772 101.765 2.303
201612 1.824 101.449 2.378
201703 1.794 102.634 2.312
201706 1.734 103.029 2.226
201709 1.693 103.345 2.167
201712 5.557 103.345 7.112
201803 5.609 105.004 7.065
201806 5.765 105.557 7.223
201809 5.239 105.636 6.559
201812 5.104 105.399 6.405
201903 5.089 106.979 6.292
201906 5.558 107.690 6.826
201909 5.569 107.611 6.845
201912 5.164 107.769 6.338
202003 4.794 107.927 5.875
202006 4.716 108.401 5.754
202009 4.516 108.164 5.522
202012 4.372 108.559 5.326
202103 4.420 110.298 5.300
202106 4.371 111.720 5.175
202109 4.317 112.905 5.057
202112 4.384 113.774 5.096
202203 4.447 117.646 4.999
202206 4.214 120.806 4.614
202209 4.097 120.648 4.491
202212 3.656 120.964 3.997
202303 3.432 122.702 3.699
202306 3.184 124.203 3.391
202309 2.966 125.230 3.132
202312 2.801 125.072 2.962
202403 2.570 126.258 2.692
202406 2.417 127.522 2.507
202409 2.248 127.285 2.336
202412 2.143 127.364 2.225
202503 1.947 129.181 1.993
202506 1.833 129.892 1.866
202509 1.682 130.290 1.707
202512 1.684 130.370 1.708
202603 1.620 132.260 1.620

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €3.63 mean?
HLS Therapeutics (FRA:74D) has a Cyclically Adjusted Book per Share of €3.63 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on HLS Therapeutics and its competitors.
Is HLS Therapeutics' Cyclically Adjusted Book per Share too high?
HLS Therapeutics' current Cyclically Adjusted Book per Share is €3.63. Overall, HLS Therapeutics has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Cyclically Adjusted Book per Share compare to ZTS and UTHR?
HLS Therapeutics' Cyclically Adjusted Book per Share of €3.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current Cyclically Adjusted Book per Share is €3.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (FRA:74D) is currently considered Fairly Valued. The stock's GF Value™ is €2.59, compared to a current price of €2.42 — trading 6.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is €3.63. HLS Therapeutics' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For HLS Therapeutics (FRA:74D), the current Cyclically Adjusted Book per Share is €3.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (FRA:74D) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of €2.42 is trading 6.6% below its estimated GF Value™ of €2.59. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for FRA:74D:

  • Cyclically Adjusted Book per Share: €3.63
  • GF Value™: €2.59 vs. price of €2.42 (6.6% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the FRA:74D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HLS Therapeutics Business Description

Other Exchanges HLTRF:USAHLS:Canada
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
63GF Score

Get the complete analysis for FRA:74D

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.42
Price
€2.59
GF Value